Beyond the ANDA: How to Use the 505(b)(2) Pathway to Build a Differentiated Drug—and Defend It
By the time a patent cliff arrives, most pharmaceutical companies have already lost the war. The moment generic manufacturers file […]
Russia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right Now
Russia is a $9.2 billion pharmaceutical market where the rulebook on intellectual property is being rewritten in real time. [1]
Russia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right Now Read Post »
Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
Prosecute to Win: Why Your Drug Patent Portfolio Is Your Next Competitive Assertion Asset The moment a generic manufacturer files
How to Forecast Generic Drug Launch Dates Using Patent Intelligence (Before Your Competitors Do)
Every year, brand-name pharmaceutical manufacturers watch billions of dollars in revenue disappear within weeks of a generic competitor hitting pharmacy
Patent Expiration Intelligence: The GPO Contract Weapon Hospitals Are Ignoring
Every three years, a hospital’s pharmacy director sits across from a GPO account team and negotiates contracts that will govern
Patent Expiration Intelligence: The GPO Contract Weapon Hospitals Are Ignoring Read Post »
Mine the FDA Orange Book for Hidden Pharma Talent: A Sourcer’s Guide to Patent Inventors and Assignees
Every pharmaceutical patent filed with the FDA Orange Book names two things: who owns the invention, and who made it.
NPV and Profitability Index: How to Rank Your Biotech R&D Portfolio
Most biotech executives say they allocate R&D capital rationally. Most are wrong. They favor programs with internal champions, compounds that
NPV and Profitability Index: How to Rank Your Biotech R&D Portfolio Read Post »
Read the Patent Cliff: How Recruiters Find Biopharma Talent Before Competitors Do
Between 2025 and 2030, the pharmaceutical industry will lose exclusivity on drugs generating more than $300 billion in annual revenue.
Read the Patent Cliff: How Recruiters Find Biopharma Talent Before Competitors Do Read Post »
Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
You probably already know the number: 80 to 90 percent. That’s how much of a branded small-molecule drug’s revenue can
